PEPTONIC medical AB (publ)

DB:28L Stock Report

Market Cap: €29.6m

PEPTONIC medical Past Earnings Performance

Past criteria checks 0/6

PEPTONIC medical's earnings have been declining at an average annual rate of -13%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 30.5% per year.

Key information

-13.0%

Earnings growth rate

16.6%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate30.5%
Return on equity-57.9%
Net Margin-148.3%
Next Earnings Update06 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How PEPTONIC medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:28L Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2433-49560
31 Mar 2439-45560
31 Dec 2337-43520
30 Sep 2341-31480
30 Jun 2343-32490
31 Mar 2344-34510
31 Dec 2244-37560
30 Sep 2239-74690
30 Jun 2234-75690
31 Mar 2229-78690
31 Dec 2132-74650
30 Sep 2133-40550
30 Jun 2135-37540
31 Mar 2131-32480
31 Dec 2021-31420
30 Sep 2014-30360
30 Jun 207-27280
31 Mar 205-26250
31 Dec 194-25240
30 Sep 194-20190
30 Jun 193-19180
31 Mar 192-17150
31 Dec 180-15140
30 Sep 180-15130
30 Jun 180-14120
31 Mar 180-13110
31 Dec 170-13110
30 Sep 170-11100
30 Jun 170-1090
31 Mar 170-1090
31 Dec 160-11100
30 Sep 160-13130
30 Jun 160-14140
31 Mar 160-15150
31 Dec 150-14140
30 Sep 150-1360
30 Jun 150-1360
31 Mar 150-1240
31 Dec 140-1030
30 Sep 140-840
30 Jun 140-730
31 Mar 140-520

Quality Earnings: 28L is currently unprofitable.

Growing Profit Margin: 28L is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 28L is unprofitable, and losses have increased over the past 5 years at a rate of 13% per year.

Accelerating Growth: Unable to compare 28L's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 28L is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).


Return on Equity

High ROE: 28L has a negative Return on Equity (-57.86%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies